Literature DB >> 27364312

Reformed smokers have survival benefits after head and neck cancer.

Wei Cao1, Zheqi Liu2, Sandhya Gokavarapu3, YiMing Chen4, Rong Yang5, Tong Ji6.   

Abstract

Smoking tobacco is the main risk factor for head and neck cancer, is proportional to the number of pack years (number of packs smoked/day x number of years of smoking), and is reduced when the patient stops smoking. Current molecular evidence has suggested that tobacco-related cancers could be clinically more aggressive than cancers in non-smokers, particularly in the head and neck. However, clinical studies have not uniformly reproduced the relation between survival and tobacco, possibly because they ignore the health benefit that reformed smokers obtain during the period between giving up smoking and the diagnosis of cancer, which is not shared by those who continue to smoke and develop cancer. We have investigated the survival of reformed smokers, non-smokers, and continuing smokers after a diagnosis of head and neck cancer. The data of patients with head and neck cancer from 1992 -2013 from the Cancer Genome Atlas database were analysed using a multivariate Cox's regression model for survival, and Kaplan-Meier curves were produced for smoking history. A total of 521 patients were treated for head and neck cancer, and there was a significant difference in survival between reformed and non-smokers on the one hand, and current smokers on the other (p=0.02). The significance increased when reformed smokers were grouped according to their duration of abstinence and time of diagnosis of cancer (>15 and ≤15 years, p<0.01). Smoking history was a significant prognostic factor in the multivariate Cox's regression model when analysed with age, stage, grade, and site. We conclude that reformed smokers have a survival benefit in head and neck cancer.
Copyright © 2016 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  diagnosis; head and neck cancer; smoking; survival; tobacco use

Mesh:

Year:  2016        PMID: 27364312     DOI: 10.1016/j.bjoms.2016.06.013

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  4 in total

1.  Prognostic nomogram based on immune scores for laryngeal squamous cell cancer.

Authors:  Lianming Liao; Wei Chen; Haichun Lai; Xuehan Yi; Desheng Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-07-08       Impact factor: 2.503

2.  Early mortality after diagnosis of cancer of the head and neck - A population-based nationwide study.

Authors:  Charbél Talani; Antti Mäkitie; Martin Beran; Erik Holmberg; Göran Laurell; Lovisa Farnebo
Journal:  PLoS One       Date:  2019-10-02       Impact factor: 3.240

3.  Electronic cigarette aerosols alter the expression of cisplatin transporters and increase drug resistance in oral cancer cells.

Authors:  Jimmy Manyanga; Vengatesh Ganapathy; Célia Bouharati; Toral Mehta; Balaji Sadhasivam; Pawan Acharya; Daniel Zhao; Lurdes Queimado
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

4.  Excision repair cross-complementing group 2 upregulation is a potential predictive biomarker for oral squamous cell carcinoma recurrence.

Authors:  Yen-Yun Wang; Pen-Tzu Fang; Chang-Wei Su; Yuk-Kwan Chen; Joh-Jong Huang; Ming-Yii Huang; Shyng-Shiou F Yuan
Journal:  Oncol Lett       Date:  2021-04-07       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.